Overview Dividends

(HOTH) Hoth Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US44148G2049

Skin, Brain, Allergy, Inflammatory, Autoimmune

HOTH EPS (Earnings per Share)

EPS (Earnings per Share) of HOTH over the last years for every Quarter: "2020-09-30": -4, "2020-12-31": -1, "2021-03-31": -6, "2021-06-30": -3.5, "2021-09-30": -3.5, "2021-12-31": -3.5, "2022-03-31": -2.75, "2022-06-30": -2.25, "2022-09-30": -2.05, "2022-12-31": -2.86, "2023-03-31": -2.86, "2023-06-30": -0.5672, "2023-09-30": -0.6, "2023-12-31": -0.32, "2024-03-31": -0.46, "2024-06-30": -0.24, "2024-09-30": -0.31, "2024-12-31": -0.32, "2025-03-31": -0.27, "2025-06-30": -0.17,
EPS Growth (3Y CAGR): 52.90%
EPS Trend (3Y Correlation): 82.4%

HOTH Revenue

Revenue of HOTH over the last years for every Quarter: 2020-09-30: 0, 2020-12-31: 0, 2021-03-31: 0, 2021-06-30: 0, 2021-09-30: 0, 2021-12-31: 0, 2022-03-31: 0, 2022-06-30: 0, 2022-09-30: 0, 2022-12-31: 0, 2023-03-31: 0, 2023-06-30: 0, 2023-09-30: 0, 2023-12-31: 0.059538, 2024-03-31: 0, 2024-06-30: 0, 2024-09-30: 0, 2024-12-31: 0, 2025-03-31: 0, 2025-06-30: 0,
Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): -4.4%

Description: HOTH Hoth Therapeutics

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company tackling unmet medical needs through innovative therapies. Their diverse pipeline includes treatments for various conditions, such as skin disorders associated with cancer therapy, mast-cell derived cancers, traumatic brain injury, Alzheimers disease, asthma, allergies, eczema, and lupus.

The companys lead candidate, HT-001, is in Phase II clinical trials, while their BioLexa Platform is in Phase I trials. With multiple license agreements with prestigious institutions, including the George Washington University and the University of Cincinnati, Hoth Therapeutics has established a strong foundation for its research and development efforts.

Analyzing the , we observe a current price of $0.84, with short-term moving averages (SMA20: $0.88, SMA50: $0.91) indicating a potential downward trend. The Average True Range (ATR) of 0.06 (7.20%) suggests moderate volatility. Given the , the companys Market Cap stands at $11.20M, with a negative P/E ratio and a Return on Equity (RoE) of -109.19, indicating significant losses.

Based on the available data, a forecast for HOTH can be constructed. The companys pipeline and license agreements are positives, but the negative financials and downward trend in the stock price are concerns. Assuming successful clinical trials and eventual commercialization of their therapies, a potential price target could be $2.50-$3.50, representing a 200-300% increase from current levels. However, this is contingent upon the company addressing its financial challenges and achieving significant milestones in its clinical trials. The high volatility and current downward trend suggest that investors should exercise caution and closely monitor the companys progress.

HOTH Stock Overview

Market Cap in USD 18m
Sub-Industry Pharmaceuticals
IPO / Inception 2019-02-15

HOTH Stock Ratings

Growth Rating -23.2%
Fundamental 23.3%
Dividend Rating -
Return 12m vs S&P 500 59.2%
Analyst Rating 4.50 of 5

HOTH Dividends

Currently no dividends paid

HOTH Growth Ratios

Growth Correlation 3m 42.1%
Growth Correlation 12m 58.6%
Growth Correlation 5y -94.4%
CAGR 5y -40.86%
CAGR/Max DD 3y -0.43
CAGR/Mean DD 3y -0.47
Sharpe Ratio 12m -0.84
Alpha 0.34
Beta 0.563
Volatility 116.60%
Current Volume 1023k
Average Volume 20d 1023k
Stop Loss 1.7 (-11.5%)
Signal -0.83

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-10.2m TTM) > 0 and > 6% of Revenue (6% = -611.2k TTM)
FCFTA -0.69 (>2.0%) and ΔFCFTA 15.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -95.11% (prev 15.6k%; Δ -15.7kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.87 (>3.0%) and CFO -8.82m > Net Income -10.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 27.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (13.2m) change vs 12m ago 91.68% (target <= -2.0% for YES)
Gross Margin 100.0% (prev 38.66%; Δ 61.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover -101.2% (prev 0.59%; Δ -101.7pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

ValueRay F-Score (Strict, 0-100) 23.29

1. Piotroski 2.0pt = -3.0
2. FCF Yield -80.75% = -5.0
3. FCF Margin -68.51% = -7.50
4. Debt/Equity 0.00 = 2.50
5. Debt/Ebitda -0.01 = -2.50
6. ROIC - WACC (= -47.17)% = -12.50
7. RoE -114.3% = -2.50
8. Rev. Trend -4.37% = -0.33
9. EPS Trend 82.45% = 4.12

What is the price of HOTH shares?

As of September 19, 2025, the stock is trading at USD 1.92 with a total of 1,022,983 shares traded.
Over the past week, the price has changed by +20.00%, over one month by +48.84%, over three months by +43.28% and over the past year by +90.10%.

Is Hoth Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Hoth Therapeutics (NASDAQ:HOTH) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 23.29 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HOTH is around 1.57 USD . This means that HOTH is currently overvalued and has a potential downside of -18.23%.

Is HOTH a buy, sell or hold?

Hoth Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy HOTH.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the HOTH price?

Issuer Target Up/Down from current
Wallstreet Target Price 5 160.4%
Analysts Target Price 5 160.4%
ValueRay Target Price 1.7 -9.4%

Last update: 2025-09-08 04:40

HOTH Fundamental Data Overview

Market Cap USD = 17.6m (17.6m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 9.01m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -10.2m + Cost of Revenue 4354 = -10.2m USD
P/B = 1.8099
Beta = 0.676
Revenue TTM = -10.2m USD
EBIT TTM = -3.48m USD
EBITDA TTM = -3.48m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 21.3k USD (from shortTermDebt, last quarter)
Debt = 21.3k USD (Calculated: Short Term 21.3k + Long Term 0.0)
Net Debt = -8.99m USD (from netDebt column, last quarter)
Enterprise Value = 8.64m USD (17.6m + Debt 21.3k - CCE 9.01m)
Interest Coverage Ratio = unknown (Ebit TTM -3.48m / Interest Expense TTM 0.0)
FCF Yield = -80.75% (FCF TTM -6.98m / Enterprise Value 8.64m)
FCF Margin = -68.51% (FCF TTM -6.98m / Revenue TTM -10.2m)
Net Margin = -100.0% (Net Income TTM -10.2m / Revenue TTM -10.2m)
Gross Margin = -100.0% ((Revenue TTM -10.2m - Cost of Revenue TTM 4354 ) / Revenue TTM)
Tobins Q-Ratio = -0.13 (set to none) (Enterprise Value 8.64m / Book Value Of Equity -66.1m)
Interest Expense / Debt = 43.66% (Interest Expense 9310 / Debt 21.3k)
Taxrate = 21.0% (US default)
NOPAT = -3.48m (EBIT -3.48m, no tax applied on loss)
Current Ratio = 27.57 (Total Current Assets 10.1m / Total Current Liabilities 364.6k)
Debt / Equity = 0.00 (Debt 21.3k / last Quarter total Stockholder Equity 9.74m)
Debt / EBITDA = -0.01 (Net Debt -8.99m / EBITDA -3.48m)
Debt / FCF = -0.00 (Debt 21.3k / FCF TTM -6.98m)
Total Stockholder Equity = 8.91m (last 4 quarters mean)
RoA = -100.8% (set to none)
RoE = -114.3% (Net Income TTM -10.2m / Total Stockholder Equity 8.91m)
RoCE = -39.04% (Ebit -3.48m / (Equity 8.91m + L.T.Debt 0.0))
RoIC = -39.04% (NOPAT -3.48m / Invested Capital 8.91m)
WACC = 8.12% (E(17.6m)/V(17.7m) * Re(8.09%)) + (D(21.3k)/V(17.7m) * Rd(43.66%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 66.67 | Cagr: 23.54%
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -6.98m)
EPS Correlation: 82.45 | EPS CAGR: 52.90% | SUE: 0.73 | # QB: 0
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for HOTH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle